![]() ![]() The decrease was primarily driven by decreased revenue recognized under the Roche collaboration agreement. Revenue: Total revenue was $2.0 million for the quarter ended March 31, 2021, as compared to $3.5 million for the quarter ended March 31, 2020. We expect cash and cash equivalents to be sufficient to fund operations into mid-2023. Initiation of a clinical trial with 4D-710 in cystic fibrosis lung disease expected in the second half of 2021įinancial Results for the First Quarter Ended March 31, 2021Ĭash and Cash Equivalents: Cash and cash equivalents were $259.9 million as of March 31, 2021.Initiation of a clinical trial with 4D-150 in wet AMD and diabetic macular edema expected in the second half of 2021. ![]() Initial clinical data from the Phase 1/2 clinical trial of 4D-125 in X-Linked Retinitis Pigmentosa (XLRP) expected in the second half of 2021.Initial clinical data from the Phase 1/2 clinical trial of 4D-310 in Fabry disease expected in the second half of 2021.Berkeley investigators Jennifer Listgarten, Ph.D and David Schaffer, Ph.D., global leaders in machine learning, computational biology, AAV directed evolution and gene therapy. This research will be conducted with U.C. Entered into a collaboration focused on applying machine learning technology to the AAV vector capsid datasets generated from 4DMT’s Therapeutic Vector Evolution platform.In addition, a preclinical acute biodistribution study demonstrated high anti-VEGF levels within the NHP eye, with no evidence of uveitis or retinal abnormality. Preclinical NHP studies demonstrated significant efficacy in the laser-induced choroidal neovascularization (CNV) model, including complete CNV suppression at the lowest dose of 1E11 vg/eye. For the first-time, 4DMT described the design of 4D-150, a dual transgene, intravitreal gene therapy designed to inhibit four distinct VEGF family members for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Presented preclinical data from non-human primate (NHP) studies at the American Society for Gene and Cell Therapy (ASGCT) 24th Annual Meeting.We also recently expanded our technology platform to include applications of machine learning, and yesterday, at the annual ASGCT conference, we presented preclinical non-human primate data from 4D-150.” In addition, we remain on track to initiate clinical trials in the second half of this year for 4D-150, our wet AMD and DME product candidate, and for 4D-710, our cystic fibrosis lung disease product candidate. ![]() “The company remains on track to announce initial clinical data from both our 4D-310 Fabry disease product candidate and our 4D-125 XLRP product candidate in the second half of this year. “We continue to relentlessly execute and innovate as demonstrated by achievements in our first full quarter as a public company,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. EMERYVILLE, Calif., (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |